Results 101 to 110 of about 8,424 (263)

A novel strategy for site selective spin-labeling to investigate bioactive entities by DNP and EPR spectroscopy

Scientific Reports, 2021
A novel specific spin-labeling strategy for bioactive molecules is presented for eptifibatide (integrilin) an antiplatelet aggregation inhibitor, which derives from the venom of certain rattlesnakes.
Kevin Herr, Max Fleckenstein, Martin Brodrecht, Mark V. Höfler, Henrike Heise, Fabien Aussenac, Torsten Gutmann, Michael Reggelin, Gerd Buntkowsky   +8 more
doaj   +1 more source

The impact of antiplatelet and anticoagulant medications on early implant failure following sinus floor augmentation: A retrospective cohort analysis

Clinical Implant Dentistry and Related Research, Volume 26, Issue 5, Page 1046-1055, October 2024.
Abstract Introduction The effect of antiplatelet and anticoagulant medications on the outcomes of sinus floor augmentation remains unclear. Methods This retrospective cohort study analyzed data from electronic medical records of consecutive patients undergoing sinus floor augmentation at a single medical center.
Ehud Jonas, Daya Masri, Gal Avishai, Hiba Masri‐Iraqi, Gavriel Chaushu, Liat Chaushu   +5 more
wiley   +1 more source

Clinical and economic studies of eptifibatide in coronary stenting [Corrigendum]

Therapeutics and Clinical Risk Management, 2014
Pasala T, Sattayaprasert P, Bhat PK, Athappan G, Gandhi S. Ther Clin Risk Manag. 2014;10:603–614.The TIMI abbreviation definition of “thrombosis in myocardial infarction” is incorrect for Table 2 on page 606 and Table 3 on page 607. It should read “thrombolysis in myocardial infarction”.Read the original article 
Ganesh Athappan, Pradeep K. Bhat, Sanjay Gandhi, Tilak Pasala, Prasongchai Sattayaprasert   +4 more
openaire   +5 more sources

Platelet glycoprotein IIb/IIIa antagonists in ischemic stroke patients without endovascular therapy: A meta‐analysis

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 44, Issue 8, Page 675-691, August 2024.
Abstract Platelet glycoprotein (GP) IIb/IIIa antagonists have been employed in selective patients after endovascular therapy (EVT) for acute ischemic stroke (AIS), yet application in patients without EVT is debated. This meta‐analysis of randomized controlled studies on AIS patients without EVT assessed the effectiveness and safety of platelet GP IIb ...
Dongjun Xu, Cheng Yang, Wei Cao, Xinyu Zhang, Shucong Yang, Xuning Shen, Jun Xu, Huijie Yu   +7 more
wiley   +1 more source

RGD-Modified Nano-Liposomes Encapsulated Eptifibatide with Proper Hemocompatibility and Cytotoxicity Effect

Iranian Journal of Biotechnology, 2019
Background Eptifibatide (Integrilin®) is a hepta-peptide drug which specifically prevents the aggregation of activated platelets. The peptide drugs are encapsulated into nanolipisomes in order to decreasing their side effects and improving their half ...
Hassan Bardania, S. Shojaosadati, F. Kobarfard, D. Morshedi, F. Aliakbari, M. Tahoori, E. Roshani   +6 more
semanticscholar   +1 more source

Priority setting for research in health care: An application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome [PDF]

, 2006
The purpose of this study is to explain the rationale for the value of information approach to priority setting for research and to describe the methods intuitively for those familiar with basic decision analytical modeling.
Bojke, L., Claxton, K., Palmer, S., Philips, Z., Sculpher, M.   +4 more
core   +1 more source

Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment

Journal of Peptide Science, Volume 30, Issue 7, July 2024.
The development of highly affine, selective peptides and small molecules in recent years has allowed peptide drugs (PDCs) and small molecule–drug conjugates (SMDCs) to increasingly compete with antibody–drug conjugates (ADCs). This review summarises and describes integrin‐addressing PDCs and SMDCs, while highlighting points of great interest.
Jannik Paulus, Norbert Sewald
wiley   +1 more source

Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice.

The Turkish Journal of Gastroenterology, 2020
BACKGROUND/AIMS To evaluate the side effects of two antiplatelet agents - ticagrelor and eptifibatide - in mice with experimentally-induced inflammatory bowel disease.
Stanko Petrović, M. Vasiljevska, S. Obradovic, D. Tarabar, R. Doder, I. Majstorović, M. Petrovic, Z. Magic, B. Cikota, N. Perisic, Irina Brčerević, N. Manojlovic, N. Rančić   +12 more
semanticscholar   +1 more source

Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. [PDF]

, 2004
AIM: To study the relationship between outcomes and peak creatine kinase (CK)-MB levels after percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute ...
Akkerhuis, K.M. (Martijn), Alexander, J.H.P. (John), Armstrong, P.W. (Paul), Califf, R.M. (Robert), Granger, C.B. (Christopher), Harrington, R.A. (Robert Alex), Kilaru, R. (Rakhi), Lincoff, A.M. (Michael), Mahaffey, K.W. (Kenneth), Moliterno, D.J. (David), Ohman, E.M. (Magnus), Roe, M.T. (Matthew), Simoons, M.L. (Maarten), Tardiff, B.E. (Barbara), Topol, E.J. (Eric), Werf, F.J.J. (Frans) van de   +15 more
core   +7 more sources

Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Non-ST-Elevation Acute Coronary Syndromes [PDF]

, 1999
BACKGROUND: Glycoprotein (GP) IIb/IIIa receptor blockers prevent life-threatening cardiac complications in patients with acute coronary syndromes without ST-segment elevation and protect against thrombotic complications associated ...
Akkerhuis, K.M. (Martijn), Boersma, H. (Eric), Califf, R.M. (Robert), Simoons, M.L. (Maarten), Théroux, P. (Pierre), Topol, E.J. (Eric)   +5 more
core